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Background. Adverse drug reactions (ADRs) are any unwanted/uncomfortable effects frommedication resulting in physical,mental,
and functional injuries. Antibiotics account for up to 40.9% of ADRs and are associated with several serious outcomes. However,
few reports on ADRs have evaluated only antimicrobial agents. In this study, we investigated antibiotic-related ADRs at a tertiary
care hospital in South Korea.Methods.This is a retrospective cohort study that evaluated ADRs to antibiotics that were reported at a
2400-bed tertiary care hospital in 2015. ADRs reported by physicians, pharmacists, and nurses were reviewed. Clinical information
reported ADRs, type of antibiotic, causality assessment, and complications were evaluated. Results. 1,277 (62.8%) patients were
considered antibiotic-related ADRs based on the World Health Organization-Uppsala Monitoring Center criteria (certain, 2.2%;
probable, 35.7%; andpossible, 62.1%). Totally, 44 (3.4%) patients experienced seriousADRs. Penicillin and quinoloneswere themost
common drugs reported to induce ADRs (both 16.0%), followed by third-generation cephalosporins (14.9%). The most frequently
experienced side effects were skin manifestations (45.1%) followed by gastrointestinal disorders (32.6%). Conclusion. Penicillin and
quinolones are the most common causative antibiotics for ADRs and skin manifestations were the most frequently experienced
symptom.
1. Introduction
Adverse drug reactions (ADRs) are any unwanted/uncom-
fortable effects frommedication resulting in physical, mental,
and functional injuries [1]. ADRs experienced by hospitalized
patients are associated with increased morbidity and mortal-
ity, prolonged hospitalization, and increasedmedical expense
[2]. For this reason, several studies have suggested that ADRs
are a major public health concern [3].
Disease prevalence, economic status, culture, and ethnic-
ity all contribute to different ADR patterns [4, 5]. The overall
incidence of ADRs varies by study but ranges from 0.15% to
30% [1, 6]. In one study conducted at an Indian tertiary care
hospital, antibiotics were responsible for 40.9% of ADRs [6].
An Australian tertiary center reported that antibiotics were
related to 25% of ADRs [7]. Furthermore, previous studies
have shown that 26.88% of ADRs are considered severe and
that 99.47% required additional medical intervention [8].
Many observational studies have examined the incidence,
pattern, and severity of ADRs, but most of these have been
performed in America or Europe; reports on Asian countries
are extremely rare [7, 9, 10]. Several South Korean reports
have identified antibiotics as a leading cause of ADRs, but
most are based on information from primary care center
pharmacies, anddata onADRs related to antimicrobial agents
reported from tertiary care hospitals are extremely rare.
Although a number of studies onADRs caused by various
drugs have been conducted, none have focused specifically
on antibiotics. Therefore, in this study we investigated the
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frequency of antibiotic-related ADRs experienced at a ter-
tiary health care hospital in South Korea.
2. Materials and Methods
2.1. Study Design. This was a retrospective cohort study
based on reports from Yonsei University College of Medicine
Severance Hospital, a tertiary health care hospital in Seoul,
South Korea, from January 1 to December 31, 2015. Only
antibiotic-related ADRs in hospitalized patients were ana-
lyzed. All antibiotics, whether administered concurrently or
at a different time point, were evaluated for possibilities of
ADRs and included in the analysis. Any cases of ADRs that
might have been caused by concurrently administered drugs,
other than antibiotics, were excluded from the analysis.
The following data were collected: date of reported ADR,
age, gender, clinical manifestation, causal drug and brand
name, route of administration, dates of administration and
discontinuation, outcome (serious or not serious), recur-
rence, causality assessment, and dose-relationship.This study
was approved by the Institutional Review Board (IRB) of
Severance Hospital (IRB #4-2017-0307), and the need for
written informed consent from all participants was waived by
the approving IRB.
2.2. Definitions. Causality was classified into three categories:
certain, probable, and possible based on the WHO-Uppsala
Monitoring Center criteria [11, 12]. The severity of each ADR
was classified as serious or nonserious [12]. Serious ADRs
were defined as patients who experienced disability, pro-
longed hospitalization, life-threatening symptoms, or death
[12]. Symptoms were classified according to symptom organ
class (SOC) from the Medical Dictionary for Regulatory
Activities (MedDRA) [13]. Defined daily dose (DDD) is the
average maintenance dose per day for a drug used for its
main purpose, as defined by the World Health Organization
(WHO) [14]. Antimicrobial use density (AUD) describes the
total antimicrobial use in DDD per 1,000 patient days of one
drug class, as recommended by the WHO [14]. AUD was
calculated as follows.
AUD = (total antimicrobial use)/(DDD × patient
days) × 1,000 [15, 16].
2.3. Collected Data and Reporting Sources. Severance Hos-
pital is a 2400-bed tertiary care hospital and is one of
the largest health care centers in South Korea. Severance
was registered as a Regional Pharmacovigilance Center in
2006 and is using a computer-based pharmacovigilance
monitoring system. ADR reporting is voluntary and can
be reported by a physician, pharmacist, nurse, or patient
who recognizes the ADR event. These voluntary reports
are reviewed by the ADR-monitoring team, which includes
a physician from the Department of Allergy and Clinical
Immunology and a pharmacist. Then the clinical and demo-
graphic information of the reported ADR is stored in a
pharmacovigilance system database and noted in the patient’s
electronic medical record (EMR). The computerized system
improves medication safety by alerting medical practitioners
to drug allergies and any drug-drug interactions the patient
experienced.
2.4. Data Analysis. Descriptive statistic procedures were
performed to analyze the ADR cases. Categorical variables
are presented as numbers and percentages. All statistical tests
were performed using SPSS 18.0 (Statistical Package for the
Social Sciences, Chicago, IL, USA).
3. Results
3.1. Demographic Data, Severity, and Causality. In total, 2,032
cases of antibiotic-related ADRs were reported during the
study period. Of these, 1,277 (62.8%) were proven to be
antibiotic-related based on the World Health Organization-
(WHO-)UppsalaMonitoringCenter criteria.Themedian age
was 54 years (range 35–78), and 610 (47.8%) patients were
male. Causality assessment based on WHO criteria revealed
that 28 (2.2%) cases were certainly caused by antibiotics, 456
(35.7%) were probably caused by them, and 793 (62.1%) were
possibly caused by them (Figure 1). A severity assessment
confirmed 44 (3.4%) serious ADRs. Death or life-threatening
events, hospital admission or prolonged hospital stay, or
disability occurred in 2 cases (4.5%), 38 cases (86.3%), and
4 cases (9.0%), respectively.
3.2. Frequency of Antibiotic-Related ADRs and Symptoms.
Penicillin and quinolones were the most frequent causes of
ADRs, and both accounted for 204 cases (16%) (Table 1).
Third-generation cephalosporins accounted for 190 cases
(14.9%), second-generation cephalosporins accounted for 144
cases (11.3%), and glycopeptides accounted for 134 cases
(10.5%).
The most common organ system affected by penicillin
was the skin and subcutaneous tissue in 88 cases (43.1%),
followed by the gastrointestinal system in 61 cases (29.9%)
and immunological system in 22 cases (10.8%). Quinolones
also commonly affected the skin and subcutaneous tissue
(98 cases, 48%), followed by the gastrointestinal system (66
cases, 32.4%) and the nervous system (16 cases 7.8%). Third-
generation cephalosporins resulted in skin and subcuta-
neous tissue reactions in 86 cases (45.3%), gastrointestinal
reactions in 79 cases (41.6), and immunological reactions
in 18 cases (9.5%). In particular, immunologic reactions,
hypersensitivity (125 cases), anaphylaxis (10 cases), Stevens-
Johnson syndrome (2 cases), and angioedema (9 cases) were
identified.
3.3. Frequency of ADRs by Symptom and the Most Common
Causative Antibiotics. Skin and subcutaneous tissue disor-
ders were themost common clinicalmanifestation, occurring
in 576 cases (45.1%), followed by gastrointestinal disorders,
which occurred in 416 cases (32.6%) (Figure 2).
Quinolones (98 cases, 17%) and penicillin (88 cases,
15.3%) were the most common causative agents for skin and
subcutaneous manifestations, followed by third-generation
cephalosporins in 86 cases (14.9%) (Table 2). Gastrointesti-
nal disorders were most often caused by third-generation
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Table 1: Antibiotics related ADR frequency and most common symptoms according to organ class (according to the preferred terms of
MedDRA coding system).
Antibiotic Patients, 𝑛 (%) Symptom organ class Frequency ofADRs, 𝑛 (%)
Penicillin 204 (16)
Skin and subcutaneous tissue
Gastrointestinal
Allergic
88 (43.1)
61 (29.9)
22 (10.8)
Quinolone 204 (16)
Skin and subcutaneous tissue
Gastrointestinal
Nervous system
98 (48.0)
66 (32.4)
16 (7.8)
3rd
cephalosporin 190 (14.9)
Skin and subcutaneous tissue
Gastrointestinal
Allergic
86 (45.3)
79 (41.6)
18 (9.5)
2nd
cephalosporin 144 (11.3)
Skin and subcutaneous tissue
Gastrointestinal
Nervous system
68 (47.2)
53 (36.8)
12 (8.3)
Glycopeptide 134 (10.5)
Skin and subcutaneous tissue
Allergic
Blood and lymphatic system
83 (61.9)
24 (17.9)
14 (10.4)
Metronidazole 61 (4.8)
Gastrointestinal
Skin and subcutaneous tissue
Nervous system
46 (75.4)
12 (19.7)
5 (8.2)
Antituberculosis
medication 61 (4.8)
Skin and subcutaneous tissue
Gastrointestinal
Hepatobiliary
Allergic
33 (54.1)
7 (11.5)
6 (9.8)
6 (9.8)
1st
cephalosporin 53 (4.2)
Skin and subcutaneous tissue
Nervous system
32 (60.4)
18 (34.0)
6 (11.3)
Carbapenem 43 (3.4)
Skin and subcutaneous tissue
Allergic
Gastrointestinal
19 (44.2)
10 (23.3)
8 (18.6)
Antifungal 33 (2.6)
Allergic
Skin and subcutaneous tissue
Cardiac
12 (36.4)
9 (27.3)
6 (18.2)
Antiviral 21 (1.6)
Skin and subcutaneous tissue
Gastrointestinal
Blood and lymphatic system
8 (38.1)
5 (23.8)
3 (14.3)
Aminoglycoside 20 (1.6)
Skin and subcutaneous tissue
Gastrointestinal
Renal and urinary
12 (60.0)
4 (20.0)
2 (10.0)
Macrolide 17 (1.3)
Gastrointestinal
Skin and subcutaneous tissue
Nervous system
7 (41.2)
5 (29.4)
3 (17.6)
Sulfonamide 16 (1.3)
Gastrointestinal
Skin and subcutaneous tissue
Renal and urinary
9 (56.2)
5 (31.2)
2 (12.5)
4th
cephalosporin 16 (1.3)
Skin and subcutaneous tissue
Gastrointestinal
Nervous system
9 (56.2)
5 (31.2)
3 (18.8)
Tetracycline 13 (1) GastrointestinalSkin and subcutaneous tissue
8 (61.5)
2 (15.4)
Antimalarial 12 (0.9)
Skin and subcutaneous tissue
Gastrointestinal
Nervous system
5 (41.7)
4 (33.3)
4 (33.3)
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Table 1: Continued.
Antibiotic Patients, 𝑛 (%) Symptom organ class Frequency ofADRs, 𝑛 (%)
Lincosamide 9 (0.7) Skin and subcutaneous tissueGastrointestinal
7 (77.8)
2 (22.2)
Polymyxin 3 (0.2) Renal and urinarySkin and subcutaneous tissue
2 (66.7)
1 (33.3)
Monobactam 1 (0.1) AllergicSkin and subcutaneous tissue
1 (100)
1 (100)
Linezolid 1 (0.1) Blood and lymphatic system 1 (100)
ADRs: adverse drug reactions.
2.2
35.7
62.1
Certain Probable Possible
4.5
86.3
9
Death Hospitalization Disability
Suspected ADR type Serious type
Figure 1: Frequency (%) of adverse drug reaction types and serious adverse drug reactions.
cephalosporins (79 cases, 19.0%), followed by quinolones (66
cases, 15.9%) and penicillin (61 cases, 14.7%).
3.4. Antimicrobial Use Density (AUD) to Demonstrate Each
Class of Antibiotics Usage. In our study, the antibiotic uses
of penicillin were 2,179.2 AUDs, followed by third-generation
cephalosporin and quinolone with AUDs of 1,277.8 and 837.9,
respectively (Supplementary Table 1).
4. Discussion
Several South Korean reports have identified antibiotics as
the most common cause of ADRs [17, 18]. However, most of
these reports have been based on data from private clinics
and pharmacies rather than tertiary care hospitals. Here, we
report the antibiotic-related ADRs experienced at a tertiary
care hospital.
In this study, 3.4% of patients experienced serious
ADRs. One multicenter study conducted in 2009 covering
six Regional Pharmacovigilance Centers in South Korea
reported that 17.7% of ADRs were serious [18]. A meta-
analysis reported that 6.7% of ADRs were serious and that
0.32% of ADRs were fatal [19]. However, it is difficult to
compare these results with our study because the previous
studies included nonantibiotics such as nonsteroidal anti-
inflammatory drugs (NSAIDs) and radiocontrast media.
Antibiotics have been reported to be major causes of
ADRs [20]. In a study that only included outpatients, sulfon-
amides followed by penicillin were reported to be the most
common causative antibiotics [20]. Prior reports have shown
that quinolones, ciprofloxacin in particular, are another com-
mon causative antibiotic [21].This study shows that penicillin
and quinolones were responsible for the majority of ADRs.
These results are similar to several other SouthKorean reports
[18, 22].
Geer et al. [6] reported that antituberculosis drugs
accounted for 13.15% of all ADRs, and Maciel et al. [23]
reported that up to 83.54% of ADRs were caused by
antituberculosis drugs. In a study in Iran, gastrointestinal
symptoms (22%) and hepatotoxicity (35.7%) were frequently
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0.2
0.3
0.4
1.8
1.8
1.9
2.4
3.4
5.3
7.1
9.8
32.6
45.1
Musculoskeletal and connective tissue
Psychiatric disorders
Eye disorder
Hepatobiliary disorders
Respiratory, thoracic, and mediastinal
Renal and urinary disorders
General and administration site disorders
Cardiac disorders
Blood and lymphatic system disorders
Nervous system disorders
Allergic disorders
Gastrointestinal disorders
Skin and subcutaneous tissue disorders
Figure 2: Frequency (%) of adverse drug reaction in symptom organ class.
Table 2: Frequency of ADRs in symptom organ class and most common causative antibiotics (according to the preferred terms of MedDRA
coding system).
Symptom organ class Patients, 𝑛(%) Antibiotics
Frequency of
ADRs, 𝑛 (%)
Skin and subcutaneous
tissue disorders 576 (45.1)
Quinolone
Penicillin
3rd cephalosporin
98 (17.0)
88 (15.3)
86 (14.9)
Gastrointestinal disorders 416 (32.6)
3rd cephalosporin
Quinolone
Penicillin
79 (19.0)
66 (15.9)
61 (14.7)
Allergic disorders 125 (9.8)
Glycopeptide
Penicillin
3rd cephalosporin
24 (19.2)
22 (17.6)
18 (14.4)
Nervous system disorders 91 (7.1)
Quinolone
3rd cephalosporin
2nd cephalosporin
16 (17.6)
14 (15.4)
12 (13.2)
Blood and lymphatic
system disorders 68 (5.3)
Penicillin
Glycopeptide
3rd cephalosporin
20 (29.4)
14 (20.6)
8 (11.8)
Cardiac disorders 43 (3.4)
Quinolone
3rd cephalosporin
2nd cephalosporin
8 (18.6)
7 (16.3)
7 (16.3)
General disorders and
administration site
conditions
31 (2.4) QuinoloneAntiviral agent
11 (61.1)
2 (11.1)
Renal and urinary disorders 24 (1.9)
Glycopeptide
Penicillin
Antifungal agent
5 (20.8)
5 (20.8)
3 (12.5)
Respiratory, thoracic, and
mediastinal disorders 23 (1.8)
3rd cephalosporin
Antifungal agent
Penicillin
6 (26.1)
5 (21.7)
4 (17.4)
Hepatobiliary disorders 23 (1.8)
Anti-TB medication
Penicillin
Carbapenem
6 (26.1)
3 (13.0)
3 (13.0)
Eye disorder 5 (0.4) Anti-TB medicationPenicillin
4 (80.0)
1 (20.0)
Psychiatric disorders 4 (0.3)
2nd cephalosporin
Carbapenem
Quinolone
2 (50.0)
1 (25.0)
1 (25.0)
Musculoskeletal and
connective tissue disorders 2 (0.2)
Penicillin
Antifungal agent
1 (50.0)
1 (50.0)
ADRs: adverse drug reactions; TB: tuberculosis.
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experienced ADRs caused by antituberculosis drugs [24]. In
this study, antituberculosis medications made up a smaller
proportion (61 cases 4.8%) ofADRs; however, gastrointestinal
reactions (11.5%) and hepatotoxicity (9.8%) were both com-
mon symptoms experienced in our study, which is similar
to the results of previous studies. Isoniazid was accountable
for nausea/vomiting in 2 cases, hepatobiliary disorders in
4 cases, and skin and subcutaneous tissue disorders in 8
cases, and 1 case was associated with anaphylaxis. Rifampin
was accountable for nausea/vomiting, skin and subcutaneous
tissue disorders, and allergic disorders in 3, 9, and 4 cases,
respectively. 1 case was associated with rifampin induced
Stevens-Johnson syndrome. Ethambutol ADRs were mostly
associated with skin and subcutaneous tissue disorders (13
cases), and ethambutol induced optic neuritis was confirmed
in 4 cases.Themajority of pyrazinamide ADRs were also skin
and subcutaneous tissue disorders, 5 cases.
Of all cutaneous ADRs considered in a previous study,
antibiotics were the main cause (46.55%) [25]; in another
study, antibiotics accounted for 48% of delayed cutaneous
ADRs, 20% of which were purportedly due to glycopeptides
and sulfonamides [26]. In particular, glycopeptides and
sulfonamides were implicated in 20% of these ADRs [26].
In our study, 45.1% of skin and soft tissue ADRs were
due to antimicrobial agents. Quinolones, penicillin, third-
generation cephalosporins, and glycopeptides were the most
common causative antibiotics for skin and subcutaneous-
related ADRs. The difference in causative antibiotics may be
explained by the ethnicities included in each study [5]. Fur-
ther studies on the mechanisms behind causative antibiotics
and reactions are needed.
Penicillin allergies are more common in females [27],
as is the frequency of ADRs [28]. We also found a slight
female predominance in our study (47.8% of patients who
experienced ADRs were male).
There were several limitations to our study. First, it
was a single-center study and lacked reports from private
clinics and other Asian countries. Further studies regarding
antibiotics and ADRs are necessary to validate our results
and provide more generalizable data covering all Asian
countries. Second, reports of ADRs are voluntary at our
hospital, so many cases could have gone unreported. Third,
only data on hospitalized patients were collected; ADRs of
outpatients were not included in the study. Finally, DDD
is a unit of measurement and does not necessarily reflect
the recommended dose or prescribed daily dose (PDD). The
PDD for each class of antibiotic was not reported by the
pharmacovigilance monitoring system used in this study. As
there is a known discrepancy between the PDD and the daily
DDD, further validation by PDDs would be necessary for
accurate comparisons between antibiotics.
5. Conclusions
In conclusion, penicillin and quinolones were the most
common antibiotic causes of ADRs. The most frequently
experienced clinical feature was skin manifestations. These
findings may help identify patterns and causative antibiotics
of ADRs in Asian countries.
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